Gilead Sciences Overview
| Company: | Gilead Sciences |
|---|---|
| CEO: | Daniel O'Day |
| Symbol: | GILD |
| Exchange: | NASDAQ |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| About |
Gilead Sciences, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences has collaboration agreements with Arcus Biosciences; Pionyr Immunotherapeutics; Tizona Therapeutics; Tango Therapeutics; Jounce Therapeutics; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics; and Merck & Co The company wasorporated in 1987 and is headquartered in Foster City, California. |
-
Ranking:
9 among 2854 companies
-
Address:
333 Lakeside Drive
-
City | State | Country:
Foster City | CA |
US
- Phone:
-
Website:
-
Revenue
Net Income
Employees
Revenue by Segment
Revenue by Region
Executive Salary
Revenue per Employee
Profit per Employee
Income Statement
Operating Income
Research & Development
Tax Rate (%)
Assets & Liabilities | Cash Flow
Total Assets
Total Liabilities
Capital Expenditure
Ratios
Return on Equity (ROE)
Return on Assets (ROA)
Debt to Equity
Profitability
Gross Profit Margin (%)
Operating Income Margin (%)
Net Income Margin (%)
Earning Per Share
EBITDA
Free Cash Flow (FCF)
Valuation
Enterprise value
Enterprise value to Revenue
Enterprise value to EBITDA
Competitors’ Revenue
Frequently Asked Questions
